vs
CareCloud, Inc.（CCLD）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CareCloud, Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$34.4M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 21.9%），CareCloud, Inc.自由现金流更多（$6.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.1%）
CareCloud, Inc.是一家上市的美国医疗信息技术企业，主要为各类医疗机构、医院提供专业医疗信息化相关服务，公司总部位于新泽西州萨默塞特，目前在全球拥有约四千名员工。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CCLD vs RGNX — 直观对比
营收规模更大
CCLD
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出21.1%
21.9%
自由现金流更多
CCLD
多$59.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.4M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 9.1% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 21.9% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.06 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCLDRGNX
| Q4 25 | $34.4M | $30.3M | ||
| Q3 25 | $31.1M | $29.7M | ||
| Q2 25 | $27.4M | $21.4M | ||
| Q1 25 | $27.6M | $89.0M | ||
| Q4 24 | $28.2M | $21.2M | ||
| Q3 24 | $28.5M | $24.2M | ||
| Q2 24 | $28.1M | $22.3M | ||
| Q1 24 | $26.0M | $15.6M |
净利润CCLDRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $3.1M | $-61.9M | ||
| Q2 25 | $2.9M | $-70.9M | ||
| Q1 25 | $1.9M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $3.1M | $-59.6M | ||
| Q2 24 | $1.7M | $-53.0M | ||
| Q1 24 | $-241.0K | $-63.3M |
毛利率CCLDRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CCLDRGNX
| Q4 25 | 9.1% | -190.0% | ||
| Q3 25 | 10.3% | -176.3% | ||
| Q2 25 | 10.9% | -296.3% | ||
| Q1 25 | 7.3% | 13.6% | ||
| Q4 24 | 12.2% | -242.1% | ||
| Q3 24 | 11.4% | -256.6% | ||
| Q2 24 | 8.1% | -251.3% | ||
| Q1 24 | 0.5% | -408.8% |
净利率CCLDRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 9.8% | -208.3% | ||
| Q2 25 | 10.6% | -331.8% | ||
| Q1 25 | 7.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 10.9% | -246.3% | ||
| Q2 24 | 6.0% | -237.7% | ||
| Q1 24 | -0.9% | -405.4% |
每股收益（稀释后）CCLDRGNX
| Q4 25 | $0.06 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $0.04 | $-1.38 | ||
| Q1 25 | $-0.04 | $0.12 | ||
| Q4 24 | $0.00 | $-0.99 | ||
| Q3 24 | $-0.04 | $-1.17 | ||
| Q2 24 | $-0.14 | $-1.05 | ||
| Q1 24 | $-0.10 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $1.2M | — |
| 股东权益账面价值 | $59.5M | $102.7M |
| 总资产 | $87.6M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CCLDRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务CCLDRGNX
| Q4 25 | $1.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $336.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CCLDRGNX
| Q4 25 | $59.5M | $102.7M | ||
| Q3 25 | $57.8M | $161.5M | ||
| Q2 25 | $56.1M | $213.7M | ||
| Q1 25 | $54.2M | $274.2M | ||
| Q4 24 | $49.8M | $259.7M | ||
| Q3 24 | $46.5M | $301.4M | ||
| Q2 24 | $43.2M | $348.3M | ||
| Q1 24 | $41.4M | $390.7M |
总资产CCLDRGNX
| Q4 25 | $87.6M | $453.0M | ||
| Q3 25 | $90.6M | $525.2M | ||
| Q2 25 | $75.2M | $581.0M | ||
| Q1 25 | $73.6M | $490.9M | ||
| Q4 24 | $71.6M | $466.0M | ||
| Q3 24 | $70.7M | $519.1M | ||
| Q2 24 | $74.0M | $569.4M | ||
| Q1 24 | $76.9M | $629.2M |
负债/权益比CCLDRGNX
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 19.0% | -174.0% |
| 资本支出强度资本支出/营收 | 6.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $23.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CCLDRGNX
| Q4 25 | $8.7M | $-52.3M | ||
| Q3 25 | $7.4M | $-56.0M | ||
| Q2 25 | $7.4M | $-49.3M | ||
| Q1 25 | $5.1M | $33.6M | ||
| Q4 24 | $5.2M | $-31.6M | ||
| Q3 24 | $7.1M | $-40.5M | ||
| Q2 24 | $4.3M | $-45.5M | ||
| Q1 24 | $4.1M | $-55.5M |
自由现金流CCLDRGNX
| Q4 25 | $6.6M | $-52.8M | ||
| Q3 25 | $6.5M | $-56.5M | ||
| Q2 25 | $6.2M | $-49.7M | ||
| Q1 25 | $4.5M | $32.6M | ||
| Q4 24 | $4.3M | $-32.7M | ||
| Q3 24 | $6.7M | $-40.9M | ||
| Q2 24 | $4.2M | $-46.0M | ||
| Q1 24 | $3.8M | $-56.0M |
自由现金流率CCLDRGNX
| Q4 25 | 19.0% | -174.0% | ||
| Q3 25 | 20.9% | -189.9% | ||
| Q2 25 | 22.8% | -232.8% | ||
| Q1 25 | 16.2% | 36.6% | ||
| Q4 24 | 15.2% | -154.2% | ||
| Q3 24 | 23.6% | -168.9% | ||
| Q2 24 | 14.8% | -206.2% | ||
| Q1 24 | 14.5% | -358.5% |
资本支出强度CCLDRGNX
| Q4 25 | 6.2% | 1.7% | ||
| Q3 25 | 2.8% | 1.7% | ||
| Q2 25 | 4.2% | 1.8% | ||
| Q1 25 | 2.3% | 1.2% | ||
| Q4 24 | 3.3% | 5.1% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率CCLDRGNX
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.62× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCLD
| Healthcare IT | $31.0M | 90% |
| Medical Practice Management | $3.4M | 10% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
